IDEXX Laboratories, Inc. $IDXX Shares Purchased by Aware Super Pty Ltd as trustee of Aware Super

Key Points

• Aware Super Pty Ltd increased its holdings in IDEXX Laboratories shares by 41.8% during the second quarter, now owning approximately $33.4 million worth of stock.
• Recent analyst reports have set optimistic price targets for IDEXX Laboratories, with values ranging from $640.00 to $785.00, and an average rating of "Moderate Buy."
• IDEXX Laboratories reported $3.63 earnings per share for the last quarter, exceeding estimates by 35 cents and demonstrating a 10.6% year-over-year revenue increase.

Aware Super Pty Ltd as trustee of Aware Super increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 41.8% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 62,291 shares of the company's stock after acquiring an additional 18,375 shares during the period. Aware Super Pty Ltd as trustee of Aware Super owned approximately 0.08% of IDEXX Laboratories worth $33,409,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of IDEXX Laboratories by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 9,855,937 shares of the company's stock valued at $4,139,001,000 after acquiring an additional 146,427 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of IDEXX Laboratories by 71.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company's stock valued at $835,244,000 after acquiring an additional 825,965 shares during the period. Invesco Ltd. grew its position in shares of IDEXX Laboratories by 0.5% during the 1st quarter. Invesco Ltd. now owns 1,166,406 shares of the company's stock valued at $489,832,000 after acquiring an additional 5,418 shares during the period. Principal Financial Group Inc. grew its position in shares of IDEXX Laboratories by 58.3% during the 1st quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company's stock valued at $472,865,000 after acquiring an additional 414,802 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of IDEXX Laboratories by 37.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,076,429 shares of the company's stock valued at $452,046,000 after acquiring an additional 290,551 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Morgan Stanley raised their price target on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the company an "overweight" rating in a research note on Friday, August 15th. Stifel Nicolaus set a $640.00 price objective on IDEXX Laboratories in a report on Monday, August 4th. JPMorgan Chase & Co. lifted their price objective on IDEXX Laboratories from $550.00 to $675.00 and gave the stock an "overweight" rating in a report on Monday, August 4th. BTIG Research lifted their price objective on IDEXX Laboratories from $545.00 to $785.00 and gave the stock a "buy" rating in a report on Tuesday, August 5th. Finally, Leerink Partners lifted their price objective on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $656.50.

IDEXX Laboratories Trading Up 0.4%

Shares of IDEXX Laboratories stock opened at $639.15 on Thursday. The stock has a market cap of $51.13 billion, a P/E ratio of 53.22, a P/E/G ratio of 4.12 and a beta of 1.58. The stock's 50 day simple moving average is $640.70 and its 200-day simple moving average is $546.36. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $688.12. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping the consensus estimate of $3.28 by $0.35. The business had revenue of $1.11 billion for the quarter, compared to analysts' expectations of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 7,143 shares of the business's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $630.43, for a total transaction of $4,503,161.49. Following the transaction, the executive vice president directly owned 18,007 shares in the company, valued at $11,352,153.01. The trade was a 28.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Sharon E. Underberg sold 5,450 shares of the business's stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $651.60, for a total value of $3,551,220.00. Following the transaction, the executive vice president owned 6,156 shares in the company, valued at approximately $4,011,249.60. This represents a 46.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 54,057 shares of company stock worth $34,293,468. 0.98% of the stock is owned by company insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.